CSIMarket Company Name, Ticker, Industry, else..
 
Landos Biopharma Inc   (NASDAQ: LABP)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 6
 Employees 27
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -25
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Business Description


Landos Biopharma Inc is a biotechnology company that focuses on developing and commercializing novel therapeutics for autoimmune diseases. The company specializes in utilizing its proprietary platform, called LANCE, to discover and develop oral peptide-based therapies that target specific disease pathways. Landos Biopharma aims to improve the quality of life for patients suffering from autoimmune diseases by providing effective and convenient treatment options.


   Company Address: P.O. Box 11239 Blacksburg 24062 VA
   Company Phone Number: 218-2232   Stock Exchange / Ticker: NASDAQ LABP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AZN   -4.25%    
GSK   -1.86%    
JNJ   -1.58%    
NVS        0.78% 
PFE        1.24% 
SNY   -2.61%    
• View Complete Report
   



Merger and Acquisition

Landos Biopharma's Groundbreaking NX-13 Provides Hope for Ulcerative Colitis Patients

Published Mon, Mar 25 2024 12:30 PM UTC


In the world of medical advancements, Landos Biopharma Inc. has emerged as a noteworthy player with its lead asset, NX-13 – a first-in-class oral NLRX1 agonist currently in Phase 2 for the treatment of ulcerative colitis (UC). With this breakthrough in hand, Landos Biopharma is poised to revolutionize the management of this debilitating inflammatory bowel disease.



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.3
Working Capital Ratio 4.43
Leverage Ratio (MRQ) 0.29
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.98 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 4.67 $
Book Value 3.73 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -918,444
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.